吲哚胺2,3-双加氧酶对接受阿扎胞苷治疗的高危骨髓增生异常综合征患者的预后价值
研究评估高危骨髓增生异常综合征(MDS)患者中吲哚胺2,3-双加氧酶(IDO-1)的表达及其与阿扎胞苷(AZA)治疗反应的关系。37%的患者呈中度至强IDO-1表达,IDO-1阳性预示治疗失败和总生存期缩短,且与CD8+ T细胞浸润减少相关。体外实验证实IDO-1+ MDS中存在色氨酸分解代谢和CD8+ T细胞耗竭。
要点
- 37%的高危MDS患者呈中度至强IDO-1表达。
- IDO-1阳性预示AZA治疗失败和总生存期缩短。
- IDO-1阳性与CD8+ T细胞浸润减少相关,AZA治疗下未见CD8+ T细胞增加。
核心结论
- IDO-1在超过三分之一的高危MDS患者中表达,预示治疗失败和总生存期缩短,正成为有前景的预测标志物和治疗靶点,尤其适用于与HMA或检查点抑制剂的联合治疗。
研究设计与样本
- 研究观察了高危MDS患者中IDO-1的表达,并进行了体外实验。
主要发现
- 37%的高危MDS患者呈中度至强IDO-1表达。
- IDO-1阳性预示治疗失败和总生存期缩短。
- IDO-1阳性与浸润性CD8+ T细胞数量呈负相关,IDO-1+患者在AZA治疗下未见CD8+ T细胞增加。
- 体外实验证实IDO-1+ MDS中存在色氨酸分解代谢和CD8+ T细胞耗竭,提示IDO-1表达诱导免疫抑制微环境,导致AZA治疗失败。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypomethylating agents (HMAs) are widely used in patients with higher-risk myelodysplastic syndromes (MDS) not eligible for stem cell transplantation; however, the response rate is <50%. Reliable predictors of response are still missing, and it is a major challenge to develop new treatment strategies. One current approach is the combination of azacytidine (AZA) with checkpoint inhibitors; however, the potential benefit of targeting the immunomodulator indoleamine-2,3-dioxygenase (IDO-1) has not yet been evaluated. We observed moderate to strong IDO-1 expression in 37% of patients with high-risk MDS. IDO-1 positivity was predictive of treatment failure and shorter overall survival. Moreover, IDO-1 positivity correlated inversely with the number of infiltrating CD8+ T cells, and IDO-1+ patients failed to show an increase in CD8+ T cells under AZA treatment. In vitro experiments confirmed tryptophan catabolism and depletion of CD8+ T cells in IDO-1+ MDS, suggesting that IDO-1 expression induces an immunosuppressive microenvironment in MDS, thereby leading to treatment failure under AZA treatment. In conclusion, IDO-1 is expressed in more than one-third of patients with higher-risk MDS, and is predictive of treatment failure and shorter overall survival. Therefore, IDO-1 is emerging as a promising predictor and therapeutic target, especially for combination therapies with HMAs or checkpoint inhibitors.
引用
- Müller-Thomas C, Heider M, Piontek G, et al. Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidine. Br J Haematol. 2020. PMID: 32350858. doi:10.1111/bjh.16652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。